How Chemist Online can help What is Glaucoma? There are several types of glaucoma, but the most common form of the disease in the UK is chronic-simple or chronic open-angle glaucoma. The condition affects your vision and becomes progressively worse with age. People of African origin are much more likely to develop glaucoma than Europeans.
This article has been cited by other articles in PMC. Abstract Background Compliance is a major issue in glaucoma care. It is usually poor in glaucomatous patients, and may ultimately result in an acceleration of the disease progression and a risk of blindness. Reasons for this poor compliance are complex and multifactorial, amongst which patient satisfaction can be counted.
The objective of this study was to develop a questionnaire to assess patient satisfaction and compliance with eye-drop treatment.
Methods A qualitative study was carried out to develop the questionnaire. An interview guide was developed based on a literature review.
Structured interviews of fifteen French and English patients with primary open-angle glaucoma or intraocular hypertension were conducted by trained interviewers of the native language of the interviewees. General concepts and subconcepts were identified from the transcripts.
The questionnaire was developed using the patient verbatim, and submitted to six patients French and English for cognitive debriefing. Following patients' comments, items were modified and restructured, and a pilot questionnaire was designed.
Results Analysis of data from the interviews with patients and clinicians resulted in the elicitation of concepts related to patient satisfaction and compliance with glaucomatous treatment. These were further refined and used to generate a test questionnaire, which consisted of 46 items grouped into 6 domains: This questionnaire could be used to evaluate patient satisfaction and compliance with eye-drop treatment and would facilitate the identification of patients at risk of being non-compliant prior to clinical trials or innovative device tests.
A psychometric study is under way to validate the questionnaire. It is a chronic disease characterised by a progressive alteration of the optic nerve, leading to visual impairment.
Glaucoma is one of the three leading causes of visual impairment in developed countries [ 12 ]. Reported increase in office visit rates is also directly associated with ageing [ 6 ].
According to the World Health Organisation, visual impairment was responsible for 2, disability-adjusted life years in high-income countries in [ 7 ]. It has considerable impact on the economy because of the non-medical costs associated with the incapacity and dependency resulting from the disease, such as loss of income, burden on carer, paid assistance and residential adaptation [ 8 ].
Visual impairment also negatively affects the Health-Related Quality of Life HRQoL of patients [ 910 ], and constitutes a major cause of disability that affects individuals, family and society, and is associated with an increased risk of institutionalisation and death [ 111 - 13 ].
Moreover, elevated IOP has been observed in patients with ocular hypertension OHTwho may never develop glaucoma [ 1415 ]. However, multiple randomised studies have established the efficacy of IOP reduction in preventing glaucomatous progression [ 16 - 19 ].
Therefore, control of IOP remains the main approach to glaucoma care, and several medical strategies have been developed to improve care: Treatment of glaucoma or OHT with medications is a major factor in the control of the progression of glaucoma, thus contributing to the maintaining of patients' HRQoL [ 1320 - 22 ].
Nevertheless, non-compliance of glaucomatous patients with the prescribed therapy is significant, and is a highly limiting factor in the management of glaucoma.
While compliance with treatment is indeed multifactorial [ 27 ], Woodside et al. This information could help characterize the treatment features that need to be improved by identifying the determinant of satisfaction. To this end, we proposed to develop a questionnaire on compliance and satisfaction with medications administered as eye-drops the Eye-Drop Satisfaction Questionnaire — EDSQ- for glaucoma or IOP treatment.
Recently, the importance of the very first steps in the development of a Patient-Reported Outcomes PRO questionnaire has been pointed out, and includes the design of a thorough and rigorous conceptual framework following patient verbatim [ 30 ].
This manuscript presents the development of the conceptual framework based on patient and clinician interviews, and the subsequent generation of the items that constitute the EDSQ.
Methods Concept development Based on patient concerns about eye-drop treatment identified in the literature review, a project team consisting of a health psychologist, two ophthalmologists and a group of experts in the development of questionnaires first met to design a list of concepts related to patients' expectations and satisfaction with eye-drop treatment.
This concept list was used for the development of the clinician and patient interview guides. Clinician interviews Five clinicians who had experience in the treatment of patients suffering from glaucoma or ocular hypertension were recruited.
Clinicians received a financial incentive for their participation. The clinician interview guide explored the following topics: Patient interviews At the time of their medical visit to their ophthalmologist, patients were asked to participate in the study. They had to be aged between 50 and 75 years; diagnosed with OHT; and be treated with one or more ophthalmic drop s.Skalicky S, Goldberg I () Depression and Quality of Life in Patients With Glaucoma: A Cross-sectional Analysis Using the Geriatric Depression Scale, Assessment of Function Related to Vision, and the Glaucoma Quality .
The United Kingdom Glaucoma Treatment Study (UKGTS) is the first randomized, double-masked, placebo-controlled, multi-centre medical treatment trial for OAG. newly-diagnosed (previously untreated) patients with OAG were prospectively recruited at 10 UK centres between and The observation period was 2 years, with .
Glaucoma is the leading cause of irreversible vision loss, worldwide. The term glaucoma includes many different diseases, which are associated with differing risk factors, symptoms, treatment, and prognosis. Glaucoma: New Data, Tools, Strategies and Insights This year’s studies profile advances in imaging, surgery, medications, nutrition, and the genesis and nature of the disease.
Glaucoma-related abstracts at this year's ARVO meeting shed light on a host of itsignficant topics. treatment of glaucoma: analysis conducted on the United Kingdom General Practitioner Research Database* A.
Lafumaa and G. Berdeauxb a Cemka, Bourg-la-Reine, France b Alcon France, Rueil-Malmaison, France Address for correspondence: Gilles Berdeaux, Alcon France, 4, Rue Henri Sainte-Claire Deville, F Rueil-Malmaison cedex, .
In the United Kingdom, the management of patients with glaucoma constitutes a major part of ophthalmologists’ workload, accounting for 23% of all follow-up attendances to the UK hospital eye service.3 In the NHS there are .